BRPI0417265A - composição farmacêutica compreendendo um princìpio ativo e sulfobetaìna - Google Patents

composição farmacêutica compreendendo um princìpio ativo e sulfobetaìna

Info

Publication number
BRPI0417265A
BRPI0417265A BRPI0417265-5A BRPI0417265A BRPI0417265A BR PI0417265 A BRPI0417265 A BR PI0417265A BR PI0417265 A BRPI0417265 A BR PI0417265A BR PI0417265 A BRPI0417265 A BR PI0417265A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
sulfobetaine
active ingredient
ndsb
relates
Prior art date
Application number
BRPI0417265-5A
Other languages
English (en)
Inventor
Viktor Menart
Vladka Gaberc Porekar
Barbara Podobnik
Original Assignee
Lek Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Pharmaceuticals filed Critical Lek Pharmaceuticals
Publication of BRPI0417265A publication Critical patent/BRPI0417265A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA COMPREENDENDO UM PRINCìPIO ATIVO E SULFOBETAìNA". A presente invenção refere-se à composição farmacêutica compreendendo um agente ativo e uma sulfobetaína não-detergente (NDSB).
BRPI0417265-5A 2003-12-23 2004-12-22 composição farmacêutica compreendendo um princìpio ativo e sulfobetaìna BRPI0417265A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI200300318A SI21639A (sl) 2003-12-23 2003-12-23 Farmacevtski pripravek, ki vsebuje nemicelarne sulfobetaine
PCT/SI2004/000043 WO2005060989A1 (en) 2003-12-23 2004-12-22 A pharmaceutical composition comprising an active principle and sulphobetaine

Publications (1)

Publication Number Publication Date
BRPI0417265A true BRPI0417265A (pt) 2007-03-06

Family

ID=34709498

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417265-5A BRPI0417265A (pt) 2003-12-23 2004-12-22 composição farmacêutica compreendendo um princìpio ativo e sulfobetaìna

Country Status (14)

Country Link
US (1) US7906109B2 (pt)
EP (1) EP1729794B1 (pt)
JP (1) JP4971798B2 (pt)
CN (1) CN1897967B (pt)
AT (1) ATE400290T1 (pt)
AU (1) AU2004305421B2 (pt)
BR (1) BRPI0417265A (pt)
CA (1) CA2545632C (pt)
DE (1) DE602004014991D1 (pt)
ES (1) ES2308292T3 (pt)
RU (1) RU2380112C2 (pt)
SI (2) SI21639A (pt)
WO (1) WO2005060989A1 (pt)
ZA (1) ZA200604657B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101116670B (zh) * 2006-08-01 2010-11-10 广州和竺生物科技有限公司 可提供活性甲基或参与甲基转移的化合物作为制备治疗病毒性疾病的药的应用
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
WO2009020744A1 (en) 2007-08-07 2009-02-12 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations comprising gdf-5 in aqueous acidic solution
BRPI0911048A2 (pt) 2008-04-14 2015-12-29 Atrm Llc formulações líquidas tamponadas de gdf-5
RU2435589C2 (ru) * 2009-06-02 2011-12-10 Федеральное государственное учреждение "Государственный научный центр дерматовенерологии и косметологии" Министерства здравоохранения и социального развития Российской Федерации (ФГУ "ГНЦДК Минздравсоцразвития России) Состав консервирующей добавки к контрольным материалам, используемым при серодиагностике сифилиса
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
CA2853112C (en) 2011-10-25 2018-08-21 Onclave Therapeutics Limited Antibody formulations and methods
GB201315321D0 (en) * 2013-08-28 2013-10-09 Koninklijke Nederlandse Akademie Van Wetenschappen Transduction Buffer
JPWO2015079977A1 (ja) * 2013-11-26 2017-03-16 シャープ株式会社 抗体分離方法、抗体評価方法、医薬の評価方法、及び、抗体の２次元電気泳動用キット
GB201521101D0 (en) 2015-11-30 2016-01-13 Koninklijke Nederlandse Akademie Van Wetenschappen Transduction buffer
CN112933039A (zh) * 2019-12-11 2021-06-11 深圳赛保尔生物药业有限公司 一种重组人促红细胞生成素液体制剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0086511B1 (en) * 1982-02-03 1986-07-02 THE PROCTER & GAMBLE COMPANY Oxygen-bleach-containing liquid detergent compositions
WO1988006041A1 (fr) * 1987-02-23 1988-08-25 Shiseido Company Ltd. Stimulateur d'absorption percutanee et preparation dermatologique pour usage externe
NZ236819A (en) * 1990-02-03 1993-07-27 Max Planck Gesellschaft Enzymatic cleavage of fusion proteins; fusion proteins; recombinant dna and pharmaceutical compositions
DE4242863A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
US5550416A (en) * 1995-02-09 1996-08-27 Fanchang; We C. Control mechanism of revolving speed of an electric tool
DE19549232C2 (de) * 1995-12-20 1998-05-20 Boehringer Mannheim Gmbh Verwendung von G-CSF in Kombination mit einem Chemotherapeutikum bei der Behandlung von Erkrankungen, die eine periphere Stammzelltransplantation erfordern
AU1528997A (en) * 1996-01-12 1997-08-01 Procter & Gamble Company, The Disinfecting compositions and processes for disinfecting surfaces
US6103683A (en) * 1996-01-12 2000-08-15 The Procter & Gamble Co. Disinfecting compositions and processes for disinfecting surfaces
HUP9900960A3 (en) * 1996-02-23 2001-02-28 Procter & Gamble Disinfecting compositions and method for disinfecting surfaces
SE9801288D0 (sv) * 1998-04-14 1998-04-14 Astra Ab Vaccine delivery system and metod of production
SI21273A (sl) * 2002-07-31 2004-02-29 LEK farmacevtska dru�ba d.d. Priprava inkluzijskih teles z visokim deležem pravilno zvitega prekurzorja heterolognega proteina

Also Published As

Publication number Publication date
DE602004014991D1 (de) 2008-08-21
WO2005060989A1 (en) 2005-07-07
ZA200604657B (en) 2007-10-31
US20070184019A1 (en) 2007-08-09
RU2006126784A (ru) 2008-01-27
SI1729794T1 (sl) 2008-12-31
CA2545632A1 (en) 2005-07-07
AU2004305421B2 (en) 2010-07-08
CN1897967A (zh) 2007-01-17
EP1729794B1 (en) 2008-07-09
ES2308292T3 (es) 2008-12-01
ATE400290T1 (de) 2008-07-15
RU2380112C2 (ru) 2010-01-27
JP2007516281A (ja) 2007-06-21
US7906109B2 (en) 2011-03-15
AU2004305421A1 (en) 2005-07-07
CA2545632C (en) 2014-10-14
EP1729794A1 (en) 2006-12-13
JP4971798B2 (ja) 2012-07-11
SI21639A (sl) 2005-06-30
CN1897967B (zh) 2010-09-08

Similar Documents

Publication Publication Date Title
NO20074807L (no) Fast farmasoytisk doseringsformulering
EP1495141A4 (en) THERAPY OF HIV
CO5611160A2 (es) Conjugados de agentes terapeuticos o citotoxicos y peptidos biologicamente activos
NO20043702L (no) 8-azaprostaglandinderivatforbindelser og legemidler inneholdende forbindelsene som den aktive bestanddel
DE50202328D1 (de) Amidofunktionelle aminopolydiorganosiloxane
JP2007504142A5 (ja) Ｈｉｖプロテアーゼ阻害薬固体分散物を含む固体薬物剤形
ATE392813T1 (de) Fungizide wirkstoffkombination
BR0207025B1 (pt) derivado de isoxazolina e herbicida contendo o mesmo como o ingrediente ativo.
DK1498411T3 (da) Diketohydrazinderivatforbindelser og medikamenter indeholdende forbindelserne som den aktive bestanddel
DK1681932T3 (da) Herbicidt aktivt middel
HRP20080564T3 (hr) Dihidrotetrabenazini i farmaceutski pripravci koji ih sadrže
ATE383771T1 (de) Fungizide wirkstoffkombinationen
PT1501534E (pt) Formulacoes farmaceuticas
ATE550941T1 (de) Synergistische insektizide mischungen
DK1557415T3 (da) Heterocykliske forbindelser og antitumorlægemidler indeholdende samme som den aktive ingrediens
MXPA05011786A (es) Combinaciones de productos activos con propiedades nematicidas, insecticidas y fungicidas, basadas en compuestos de trifluorbutenilo.
DK1596870T3 (da) Höjdosis-iblandronatformulering
ATE454385T1 (de) Hiv-integrase-hemmers, pharmazeutischen zusammensetzung und ihre anwendung
NO20063393L (no) Farmasoytiske preparater
ITMI20031714A1 (it) Formazioni ad azione antitumorale.
TW200621160A (en) Anti-termite agent
SI1729794T1 (sl) Farmacevtski pripravek, ki vsebuje sulfobetain, ki nima lastnosti detergenta
NO20054214D0 (no) Iminoeterderivatforbindelser og legemidler inneholdende forbindelsene som den aktive bestanddel
BRPI0417205A (pt) composições farmacêuticas
EP1513544A4 (en) RETROYCLINE: ANTIVIRAL AND ANTIMICROBIAL PEPTIDES

Legal Events

Date Code Title Description
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 8A E 9A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2259 DE 22/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 8A, 9A, 10A, 11A, 12A, 13A, 14A E 15A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.